Boehringer Seeks To Rebalance Immunity With Sitryx Collab Potentially Worth $500M+

February 26, 2026

Boehringer bets up to $500m on Sitryx immunology programme

February 26, 2026

Boehringer Ingelheim Acquires Exclusive License from Sitryx Therapeutics for Preclinical Small Molecule Program

February 26, 2026

Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics

February 26, 2026

Evommune Announces $125 Million Private Placement

February 17, 2026

Evommune’s Dupixent-like phase 2 eczema data drive 75% stock rally

February 11, 2026